Jan 31 (Reuters) - Aviragen Therapeutics Inc:
* CAS GROUP ANNOUNCES GLASS LEWIS RECOMMENDATION THAT AVIRAGEN STOCKHOLDERS VOTE AGAINST MERGER AND EMPHASIZES VALUE OF TESLEXIVIR (BTA074) PROGRAM Source text for Eikon: Further company coverage:
 